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Inflammation and dyslipidemia in 
nephropathy: an epidemiologic 
perspective
SL Seliger1
The association of dyslipidermia and inflammatory markers 
with decreased renal function has been reported in several large 
epidemiologic studies. In this issue, Lin et al examine these associations 
among middle-aged and older type 2 diabics, a population at high risk 
for chronic kidney disease. Their findings support a role for these factors 
in the pathogenesis of progressive renal disease.
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Th e crucial role of dyslipidemia in the pro-
gression of proteinuric kidney disease was 
fi rst described systematically more than 20 
years ago by Moorhead et al.1,2 Th ey pro-
posed a model in which quantitative and 
qualitative changes in circulating lipopro-
teins, representing metabolic responses 
to proteinuria, result in mesangial-cell 
injury, activation, and proliferation, as 
well as injury to glomerular epithelial 
cells and basement membrane. Th e result-
ing cellular injury and activation in turn 
lead to excess production of extracellular 
matrix and progressive glomerulosclero-
sis. Concurrently, accelerated atheroscle-
rosis induced by the hyperlipidemia, and 
progressive tubulo-interstitial fi brosis as 
a reaction to reabsorption of fi ltered lipo-
proteins, contribute to the global nephro-
sclerosis process, resulting ultimately in 
chronic renal failure.
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Since the publication of this hypoth-
esis, a considerable body of evidence 
from in vitro and in vivo animal model 
experiments has supported this model 
of progressive renal injury. Th ese stud-
ies have also revealed the importance 
of an intermediate infl ammatory proc-
ess in contributing to the progressive 
nephrosclerosis. Th is infl ammation is 
characterized histologically by a mono-
cyte/macrophage infi ltrate and at the 
molecular level by increased production 
of chemokines including tumor necrosis 
factor-α, RANTES, vascular cell adhe-
sion molecule, and intercellular adhe-
sion molecule. Central to this model 
of lipid nephrotoxicity mediated by 
monocytic infl ammation is the concept 
of a positive-feedback loop, in which 
the progressive mesangial, epithelial, 
and tubulo-interstitial injury results in 
worsening proteinuria and renal fi ltra-
tion function, which in turn lead to more 
severe dyslipidemia and infl ammation. 
Moorhead termed this feedback loop the 
“lipoprotein injury cycle.”2
Th e implication of these fi ndings from 
experimental models is that one could 
prevent or at least attenuate the process 
of progressive nephrosclerosis through 
interventions aimed at certain mediators 
of this cycle. However, it has not been 
clear whether these lipid and infl am-
matory factors are important in the 
development and progression of diverse 
forms of human kidney disease. Except 
for very rare inherited defi ciencies of 
lipoprotein metabolism, humans with 
isolated dyslipidemia but without other 
risk factors do not generally develop pro-
gressive glomerulosclerosis, in contrast 
to the experimental models described 
by Moorhead et al. and others. On the 
other hand, it is entirely plausible that 
in the setting of primary renal disease or 
systemic conditions known to injure the 
kidney (for example, sustained hypergly-
cemia or systemic hypertension), these 
factors play a major role in the initiation 
and progression of kidney disease.
However, there are considerable meth-
odological challenges to demonstrating 
these effects in large, heterogeneous 
human populations. As with all obser-
vational epidemiologic research, the 
accurate ascertainment of exposures and 
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outcomes is essential to successful detec-
tion of these associations. For ascertain-
ment of infl ammatory factors, practical 
and ethical restrictions preclude obtain-
ing renal biopsy specimens in large pop-
ulations; therefore, evaluation is limited 
to measurements of serum markers. 
With regard to ascertainment of the out-
come of chronic kidney disease (CKD), 
the challenges in accurately measur-
ing renal function in large populations 
are well known.3 Direct measurement 
of glomerular fi ltration rate (GFR) has 
generally not been considered feasible, 
although it is currently being performed 
in the ongoing Chronic Renal Insuffi  -
ciency Cohort study. Serum creatinine is 
the only renal function marker available 
in many large cohort studies, but as cre-
atinine generation is dependent on mus-
cle mass, and infl ammation is a putative 
factor in determining loss of muscle 
mass, a biased estimate of the associa-
tion between creatinine and infl amma-
tion is possible. Th e Modifi cation of Diet 
in Renal Disease estimating equation, 
which was developed in a CKD popula-
tion, signifi cantly underestimates GFR 
in individuals without CKD;4 therefore, 
when it is applied to large populations 
with mostly intact renal function, there 
is a great potential for misclassifi cation 
of individuals as having a GFR above or 
below a threshold considered to defi ne 
CKD. Diff erential calibration of creati-
nine assays is probably a major source 
of error in this estimating equation, and 
therefore calibration to the Modifi cation 
of Diet in Renal Disease core laboratory 
may reduce this misclassifi cation. Th e 
use of alternative serum markers such 
as cystatin C to ascertain renal function 
in epidemiologic studies appears prom-
ising5 but requires further evaluation.
Adding to these methodological chal-
lenges is the extreme paucity of epide-
miologic studies designed specifi cally 
to study risk factors for the progres-
sion of CKD. However, a number of 
cardiovascular studies have served as 
data sources for secondary analyses 
of factors related to CKD, and these 
have consistently found associations 
of dyslipidemia and increased systemic 
infl ammation with either the presence 
of low GFR or a longitudinal decrease 
in GFR.6–9 In the current issue, Lin et 
al.10 provide further evidence for this 
association among middle-aged and eld-
erly type 2 diabetics, a population that 
is growing rapidly and that is clearly at 
high risk for CKD. Th e authors exam-
ined the association of lipids and serum 
markers of infl ammation with low GFR 
among 732 middle-aged and elderly 
males with type 2 diabetes, as part of the 
Health Professionals’ Follow-Up Study. 
Of these, 90 had an estimated GFR less 
than 60 cc/min/1.73 m2. Among infl am-
matory markers, the authors found an 
association between low GFR and vas-
cular cell adhesion molecule and solu-
ble tumor necrosis factor-α receptor 2 
— important factors in the monocytic 
infi ltration observed in experimental 
models of CKD. Higher fi brinogen was 
also associated with low GFR, consistent 
with results from other cohorts; it has 
been suggested that this association may 
mediate some of the increased vascular 
risk observed in CKD.
Among lipid and lipoprotein meas-
ures, a high triglyceride level and a low 
high-density lipoprotein level were 
both associated with an increased risk 
of low GFR. Similar associations have 
been reported in several other large 
cardiovascular cohorts. Th ese are also 
common abnormalities in diabetes and 
relate to the severity of hyperglycemia 
and insulin resistance. It is possible, 
therefore, that the observed association 
represents an eff ect of hyperglycemia of 
greater severity or longer duration rather 
than dyslipidemia, although adjustment 
was made for a single measure of gly-
cosylated hemoglobin and for duration 
of diabetes. In contrast, no consistent 
association with low GFR was seen 
for low-density lipoprotein (LDL) or 
non-high-density lipoprotein choles-
terol (the latter measure includes both 
LDL and very low-density lipoprotein 
components). Other population-based 
studies have also generally failed to fi nd 
this association. However, this may not 
indicate that LDL is unimportant in con-
tributing to CKD or increasing vascular 
risk in this population. Qualitative alter-
ations to LDL particles that are believed 
to promote renal injury and atherogen-
esis have been described in experimental 
models and human patients with CKD. 
Th ese include triglyceride enrichment of 
LDL, resulting in small, dense particles, 
as well as oxidative modifi cation. Ascer-
tainment of these types of abnormalities 
in a large prospective cohort might pro-
vide important information on their role 
in progression of human renal disease.
As the authors noted,10 there were no 
measurements of urine protein available 
in their study population, a signifi cant 
limitation given the importance of pro-
teinuria as an indicator of renal injury 
and as a possible determinant of hyper-
lipidemia and even of systemic infl am-
mation. Th e cross-sectional nature of 
the analysis precludes an answer to the 
question of the causal direction of the 
relationship of dyslipidemia and infl am-
mation with GFR. Th e study population 
was entirely male and overwhelmingly 
Caucasian; it will be important to dem-
onstrate that these relationships are also 
present in other demographic groups.
The study by Lin et al.10 illustrates 
both the strengths and the limitations 
inherent in testing hypotheses related 
to renal disease in databases originally 
designed to study cardiovascular disease. 
Analyses of such data sets have yielded 
invaluable information on risk factors 
for renal disease and have linked CKD 
to a wide range of adverse cardiovascu-
lar outcomes. On the other hand, the 
absence of measurements of proteinuria 
and direct measurements of GFR, and 
(for some cohorts) the relatively low 
frequency of clinically signifi cant renal 
disease, limit the hypotheses that can be 
fully explored. Nevertheless, Lin et al.10 
have contributed important information 
regarding the relationship of inflam-
mation and dyslipidemia with renal 
impairment in diabetes. Th e cumulative 
evidence from experimental models and 
population-based studies supports the 
evaluation of interventions that target 
these factors in both diabetic and non-
diabetic patients with CKD.
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T cells and T-cell receptors in acute 
renal failure
Didier Portilla1 and Mark D Okusa2
T cells are activated by antigen-independent as well as antigen-
dependent mechanisms during ischemia-reperfusion injury to the 
kidney. In the current issue, a study by Savransky et al. suggests that 
antigen-dependent activation of T-cell receptors further contributes 
to the pathogenesis of ischemia-reperfusion injury.
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Although the participation of lymphocytes 
in kidney ischemia-reperfusion injury (IRI) 
has gained recent interest, there are con-
siderable gaps in our knowledge. Insight 
into the kinetics of T-cell infi ltration and 
into the way these cells participate in the 
classical paradigm of T-cell activation has 
remained elusive. Th ere is evidence indicat-
ing that antigen-independent activation of 
T cells occurs through cytokines and reac-
tive oxygen intermediates. However, in this 
issue, Savransky et al.1 report on a series of 
experiments that suggest that T-cell recep-
tors (TCRs) participate in the pathogen-
esis of IRI, thus potentially advancing our 
knowledge of how the innate and adaptive 
immune systems participate in IRI.
Ischemia-reperfusion injury: innate and 
adaptive immune system
The rapid appearance within kidney 
tissue of components of the innate 
immune system, such as neutrophils and 
macrophages, following IRI provides 
clear support for an antigen-independ-
ent mechanism of tissue injury.2,3 The 
innate immune system has evolved as a 
host defense mechanism that recognizes 
microbial products. Toll-like receptors 
and a limited number of other receptors 
appear to respond to highly conserved 
structures referred to as pathogen-asso-
ciated molecular patterns that are released 
by microbes or apoptotic or necrotic tissue 
components.4 Once activated, an infl am-
matory and immune response leads to 
leukocyte sequestration in infl amed sites, 
complement activation, and eradication 
of pathogen through cytokines, comple-
ment/membrane attack complex, and 
natural killer cells. Activation of kidney 
resident dendritic cells leads to a pheno-
typic switch from an immature cell type 
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characterized by high phagocytic capac-
ity, low class II major histocompatibility 
complex, and co-stimulatory proteins to 
a mature cell type characterized by low 
phagocytic capacity, high surface expres-
sion of class II major histocompatibility 
complex, and co-stimulatory molecules, 
thereby permitting T-cell activation.5–7 
Th us, in addition to antigen-independ-
ent activation of T cells through reactive 
oxygen species, interferon-γ, and other 
cytokines, antigen-dependent activa-
tion of T cells may occur through anti-
gen presentation by dendritic cells, the 
major antigen-presenting cell (APC) in 
the kidney. In a recent study, Dong et al.8 
demonstrated activated traffi  cking of den-
dritic cells following IRI by showing their 
capacity to migrate to the kidney draining 
lymph node, leading to antigen presenta-
tion and activation of naive T cells. Aft er 
T-cell activation and proliferation, these 
T cells may participate in the later phases 
of IRI.
Signals involved in T-cell activation 
during acute renal failure
Th e mechanisms of T-cell activation have 
not been completely elucidated. A general 
property of lymphocytes, including T cells, 
is the need for two distinct extracellular 
signals (TCR signal and co-stimulatory 
signal) in order to induce proliferation 
and diff erentiation into eff ector cells. Th e 
fi rst signal is provided by antigen binding 
to the major histocompatibility complex 
molecules in the APCs. In the case of 
T cells, peptide major histocompatibility 
complex binding to the TCR and CD4 and 
CD8 co-receptors provides signal 1. How-
ever, the antigen-specifi c clonal expansion 
of naive T cells requires a second co-stimu-
latory signal that must be delivered by the 
same APC on which the T cell recognizes 
its specifi c antigen. Th e best-character-
ized co-stimulatory molecules on APCs 
are the structurally related glycoproteins 
B7.1 (CD80) and B7.2 (CD86), which 
are also called B7 molecules. The B7 
molecules are homodimeric members of 
the immunoglobulin superfamily, found 
exclusively on the surface of cells capable 
of stimulating T-cell growth. Th e receptor 
for B7 molecules on the T cell is CD28, 
another member of the immunoglobu-
lin superfamily. Ligation of CD28 by B7 
